Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden

Klok, Rogier M.; Lindkvist, Rose-Marie; Ekelund, Mats; Farkouh, Raymond; Strutton, David

doi:10.1016/j.clinthera.2012.12.006

Cited by 48 publications

(31 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, surveillance from PCV10-only countries have failed to show any sustained reduction in 19A invasive disease, as previously discussed. [22][23][24][25] Second, there have not been any conclusive evidence of the lack of PCV13 effectiveness against serotype 3. Finally the assumption that PCV10 has effectiveness against NTHi disease has been widely and repeatedly challenged.…”

Section: Discussionmentioning

confidence: 99%

“…Finally the assumption that PCV10 has effectiveness against NTHi disease has been widely and repeatedly challenged. [22][23][24][26][27][28][29][30][31][32] In addition, of note, by definition, IPD is a severe condition caused by streptococcus pnemoniae, not caused by NTHi. The assumption that PCV10 provided protection against invasive NTHi is not supported by any scientific evidence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: herd effect, incremental cost-effectiveness ratio (ICER), Markov transition-state model, pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13), 10-valent pneumococcal conjugate vaccine (PCV10)Pneumococcal disease causes large morbidity, mortality and health care utilization and medical and non-medical costs, which can all be reduced by effective infant universal routine immunization programs with pneumococcal conjugate vaccines (PCV). We evaluated the clinical and economic benefits of such programs with either 10-or 13-valent PCVs in Malaysia and Hong Kong by using an age-stratified Markov cohort model with many country-specific inputs. The incremental cost per quality-adjusted life year (QALY) was calculated to compare PCV10 or PCV13 against no vaccination and PCV13 against PCV10 over a 10-year birth cohort's vaccination. Both payer and societal perspectives were used. PCV13 had better public health and economic outcomes than a PCV10 program across all scenarios considered. For example, in the base case scenario in Malaysia, PCV13 would reduce more cases of IPD (C2,296), pneumonia (C705,281), and acute otitis media (C376,967) and save more lives (C6,122) than PCV10. Similarly, in Hong Kong, PCV13 would reduce more cases of IPD cases (C529), pneumonia (C172,185), and acute otitis media (C37,727) and save more lives (C2,688) than PCV10. During the same time horizon, PCV13 would gain over 74,000 and 21,600 additional QALYs than PCV10 in Malaysia and Hong Kong, respectively. PCV13 would be cost saving when compared against similar program with PCV10, under both payer and societal perspective in both countries. PCV13 remained a better choice over PCV10 in multiple sensitivity, scenario, and probabilistic analyses. PCV13s broader serotype coverage in its formulation and herd effect compared against PCV10 were important drivers of differences in outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…In a report from Sweden and Denmark [60], a study from Greece, Germany and the Netherlands [61], and another from Gambia [62], PCV13 prevented more cases of IPD and deaths and gained more quality adjusted Life Years (QALYs) than PCV10. The same results were observed in Canada, which had a 2 + 1 PCV schedule like that of Peru [63].…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru

Mezones‐Holguín

Canelo‐Aybar

Clark

et al. 2015

Vaccine

View full text Add to dashboard Cite

a b s t r a c tObjective: To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods: The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings: For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS;and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion: Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.

show abstract

“…В связи с отсутствием российских данных по летальности паци-ентов с пневмококковой бактериемией данная величи-на была принята равной таковой при пневмококковом менингите, т. е. 17,9% [7].…”

Section: заболеваемость пневмококковой бактериемиейunclassified

“…Предполагали, что эффективность ПКВ13 в отноше-нии амбулаторных острых средних отитов любой этиоло-гии составит 5% [7].…”

Section: эффективность вакцины в вакцинированной популяцииunclassified

Pharmacoeconomic Assessment of 13-Valent Pneumococcal Conjugate Vaccine in Immunization of Children in Russian Federation

Рудакова¹,

Баранов²,

Lobzin³

et al. 2014

View full text Add to dashboard Cite

Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden

Cited by 48 publications

References 55 publications

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru

Pharmacoeconomic Assessment of 13-Valent Pneumococcal Conjugate Vaccine in Immunization of Children in Russian Federation

Contact Info

Product

Resources

About